{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 291,
  "pageCount": 366,
  "prevPage": 290,
  "nextPage": 292,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to provide expert validation that scheduling is not a significant barrier to prescription.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/291",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-291",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "the folks at Harmony market that stronger than probably it carries with clinicians",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abbb-928874ea01f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "“It’s not that big a deal”; Scheduled substances can still be prescribed for up to 6 months at a time\nQ: “When something is Schedule 3 or Schedule 4, like Xyrem or modafinil, what is the requirement? How often does the patient—what is onerous about it being Schedule 3 or Schedule 4? What requirements does that involve?”\nA: “Not much. Schedule 3 and Schedule 4 can both be written with refills going as much as 6 months. My Xywav prescriptions, I have to refill twice a year, the same thing with modafinil. So, it’s not nearly as onerous as Adderall, where you have to write a new script every month...Schedule 2s are more annoying. Three and 4 are the same, honestly. It’s not that big a deal.”\nQ: “And most of the drugs in this category are Schedule 3 and 4? The common ones?”\nA: “All of the stimulants are Schedule 2. So, Schedule 3 is just Xyrem and Xywav, and Schedule 4 is modafinil, armodafinil, and Sunosi. All of the stimulants: Adderall, Vyvanse, and Ritalin, are all Schedule 2.” – Medical advisor to Harmony",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30e8439b-4df9-43ad-a451-9e721e5bc467",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.86,
        "x": 0.07,
        "y": 0.61
      },
      "kind": "paragraph",
      "text": "Incremental benefit at best; docs have to prescribe scheduled substances anyway\nQ: “How much of an advantage is that Wakix is not controlled – aren’t all the people prescribing this already registered with the DEA?”\nA: “It depends. Your point is well taken. For instance, from my perspective, most patients I treat with narcolepsy are going to be a 2 or 3-agent regimen, and those are going to involve things that are at least Schedule 4, sometimes Schedule 2, and Xyrem in between Schedule 3...there are other clinics that are very, very happy to just keep writing stimulants for everybody, and they don’t want to deal with this, but at the same time, those are the people who are the most resistant, I think, oxybate, and the fact that this is a simple regimen, that also is a factor. I think the major challenge for any of the newer agents, there’s a lot of inertia for some of these clinics where stimulants get approved, they’re cheap, you write it, the patient goes and picks it up at the pharmacy, that’s it. There’s no prior auth, there’s no appeal, there’s no annoying paperwork. And that happens with oxybate and with pitolisant. So, some people, whatever they say, they just don’t want to deal with it. But that was a tangential answer, I’m sorry. But I do think it has some benefit to having it not being controlled. I think that the folks at Harmony market that stronger than probably it carries with clinicians, but it’s not nothing.”\nQ: “No, I get it. It’s an incremental benefit.”\nA: “Yeah.” – Medical advisor to Harmony",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a474813a-f1a7-441d-aafd-b309eef244b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "A physician who is a medical advisor to Harmony concurred, saying “it’s not that big a deal” as scheduled drugs can still be prescribed for 6 months at a time, particularly key competitors like Xywav and Xyrem, and that the additional work is “not much.” He stated he already has to write scheduled drugs for all the same patients anyway: “most patients I treat with narcolepsy are going to be a 2 or 3-agent regimen, and those are going to involve things that are at least Schedule 4.” He added that “the folks at Harmony market that stronger than probably it carries with clinicians” and indicated it’s at best an incremental benefit.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc0b5793-46c0-4411-921a-6c70b1c4a0c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“it’s not that big a deal” — Medical advisor to Harmony; “most patients I treat with narcolepsy are going to be a 2 or 3-agent regimen, and those are going to involve things that are at least Schedule 4.” — Medical advisor to Harmony; “the folks at Harmony market that stronger than probably it carries with clinicians” — Medical advisor to Harmony",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abbb-9459012db23b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad944070-3901-4b63-9a84-a49fd5cdf6bf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}